Companies › Chongqing Claruvis Pharmaceutical
1 active drug program in 4 registered trials: 3 Phase 3, 1 Phase 2; Neurology, Other; next expected readout Jun 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Recombinant Botulinum Toxin Type A (YY001) | – | Phase 3 | Upper Limb Spasticity; Moderate to Severe Glabellar Lines; Upper Limb Spasticity (ULS) | Jun 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06937944 | Recombinant Botulinum Toxin Type A (YY001) | Phase 3 | Moderate to Severe Glabellar Lines | Other | Feb 2026 |
| NCT06783114 | Recombinant Botulinum Toxin Type A (YY001) | Phase 2 | Upper Limb Spasticity | Neurology | Sep 2026 |
| NCT07242300 | Recombinant Botulinum Toxin Type A (YY001) | Phase 3 | Upper Limb Spasticity (ULS) | Neurology | Dec 2026 |
| NCT07478822 | Recombinant Botulinum Toxin Type A (YY001) | Phase 3 | Upper Limb Spasticity | Neurology | Jun 2027 |
No annotated target.
–
Pharmazz Incepta Pharmaceuticals Sandoz Neurona Therapeutics Merz Pharmaceuticals
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.